Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Feb 6;3:14.
doi: 10.3389/fendo.2012.00014. eCollection 2012.

Recruitment of Brown Adipose Tissue as a Therapy for Obesity-Associated Diseases

Free PMC article

Recruitment of Brown Adipose Tissue as a Therapy for Obesity-Associated Diseases

Olivier Boss et al. Front Endocrinol (Lausanne). .
Free PMC article


Brown adipose tissue (BAT) has been recognized for more than 20 years to play a key role in cold-induced non-shivering thermogenesis (CIT, NST), and body weight homeostasis in animals. BAT is a flexible tissue that can be recruited by stimuli (including small molecules in animals), and atrophies in the absence of a stimulus. In fact, the contribution of BAT (and UCP1) to resting metabolic rate and healthy body weight homeostasis in animals (rodents) is now well established. Many investigations have shown that resistance to obesity and associated disorders in various rodent models is due to increased BAT mass and the number of brown adipocytes or UCP1 expression in various depots. The recent discovery of active BAT in adult humans has rekindled the notion that BAT is a therapeutic target for combating obesity-related metabolic disorders. In this review, we highlight investigations performed in rodents that support the contention that activation of BAT formation and/or function in obese individuals is therapeutically powerful. We also propose that enhancement of brown adipocyte functions in white adipose tissue (WAT) will also regulate energy balance as well as reduce insulin resistance in obesity-associated inflammation in WAT.

Keywords: BAT; brown adipose tissue; human; progenitors; recruitment; therapy.


Figure 1
Figure 1
The discovery of brown adipocyte stem/progenitor cells in humans of all ages provides an essential tool for drug discovery. The cells could also be expanded and induced to differentiate in culture, and transplanted back to the patient. Increasing the amount of brown adipose tissue (through recruitment or transplantation) is expected to improve glucose metabolism (diabetes), lower body fat (obesity), and ameliorate dyslipidemia and cardiovascular disease risks.

Similar articles

See all similar articles

Cited by 27 articles

See all "Cited by" articles


    1. Ailhaud G., Grimaldi P., Negrel R. (1992). Cellular and molecular aspects of adipose tissue development. Annu. Rev. Nutr. 12, 207–23310.1146/ - DOI - PubMed
    1. Almind K., Manieri M., Sivitz W. I., Cinti S., Kahn C. R. (2007). Ectopic brown adipose tissue in muscle provides a mechanism for differences in risk of metabolic syndrome in mice. Proc. Natl. Acad. Sci. U.S.A. 104, 2366–237110.1073/pnas.0610416104 - DOI - PMC - PubMed
    1. Arch J. R. (2002). Beta(3)-adrenoceptor agonists: potential, pitfalls and progress. Eur. J. Pharmacol. 440, 99–10710.1016/S0014-2999(02)01421-8 - DOI - PubMed
    1. Arch J. R. (2008). The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from beta3-adrenoceptor agonists. Naunyn Schmiedebergs Arch. Pharmacol. 378, 225–24010.1007/s00210-008-0271-1 - DOI - PubMed
    1. Bar-Shalom R., Gaitini D., Keidar Z., Israel O. (2004). Non-malignant FDG uptake in infradiaphragmatic adipose tissue: a new site of physiological tracer biodistribution characterised by PET/CT. Eur. J. Nucl. Med. Mol. Imaging 31, 1105–111310.1007/s00259-004-1506-0 - DOI - PubMed

LinkOut - more resources